Lipid Biomarkers for Risk Assessment in Acute Coronary Syndromes

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Current Cardiology Reports

• Publication date

  2017-04-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11886-017-0863-9PMID 28432661
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Omega-3 and Trans Fatty Acids in Middle Aged-Acute Coronary Syndrome Patients

  2018cited by this paper
• Oxidized Phospholipids on Apolipoprotein B-100 and Recurrent Ischemic Events Following Stroke or Transient Ischemic Attack.

  2017cited by this paper
• A Meta‐Analysis of Randomized Controlled Trials and Prospective Cohort Studies of Eicosapentaenoic and Docosahexaenoic Long‐Chain Omega‐3 Fatty Acids and Coronary Heart Disease Risk

  2017cited by this paper
• Should apolipoprotein B replace LDL cholesterol as therapeutic targets are lowered?

  2016cited by this paper
• 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.

  2016cited by this paper
• Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology

  2016cited by this paper
• Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol

  2016cited by this paper
• Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Med

  2016cited by this paper
• Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization.

  2016cited by this paper
• Comparative effects of high-dose atorvastatin versus moderate-dose rosuvastatin on lipid parameters, oxidized-LDL and inflammatory markers in ST elevation myocardial infarction.

  2015cited by this paper
• Omega-3 fatty acids in cardiovascular disease--an uphill battle.

  2015cited by this paper
• National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2.

  2015cited by this paper
• Ceramide is upregulated and associated with mortality in patients with chronic heart failure.

  2015cited by this paper
• Plasma concentrations of molecular lipid species in relation to coronary plaque characteristics and cardiovascular outcome: Results of the ATHEROREMO-IVUS study.

  2015cited by this paper
• Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis.

  2015cited by this paper
• Reliability of Calculated Low-Density Lipoprotein Cholesterol.

  2015cited by this paper
• Lipid parameters in patients with acute coronary syndromes versus stable coronary artery disease

  2015cited by this paper
• Serum sphingolipids: relationships to insulin sensitivity and changes with exercise in humans.

  2015cited by this paper
• Lipoprotein(a) mass: a massively misunderstood metric.

  2014cited by this paper
• National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary.

  2014cited by this paper
• Dose-dependent effects of rosuvastatin on the plasma sphingolipidome and phospholipidome in the metabolic syndrome.

  2014cited by this paper
• Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study.

  2014cited by this paper
• 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

  2014cited by this paper
• Reprint: 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk.

  2014cited by this paper
• Endogenous Ceramide Contributes to the Transcytosis of oxLDL across Endothelial Cells and Promotes Its Subendothelial Retention in Vascular Wall

  2014cited by this paper
• 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

  2014cited by this paper
• Discordance of Low-Density Lipoprotein (LDL) Cholesterol With Alternative LDL-Related Measures and Future Coronary Events

  2014cited by this paper
• Genetic associations with valvular calcification and aortic stenosis.

  2013cited by this paper
• Molecular Lipids Identify Cardiovascular Risk and Are Efficiently Lowered by Simvastatin and PCSK9 Deficiency

  2013cited by this paper
• Lipoprotein Apheresis in Patients With Maximally Tolerated Lipid-Lowering Therapy, Lipoprotein(a)-Hyperlipoproteinemia, and Progressive Cardiovascular Disease: Prospective Observational Multicenter Study

  2013cited by this paper
• Comparative effects of an acute dose of fish oil on omega-3 fatty acid levels in red blood cells versus plasma: implications for clinical utility.

  2013cited by this paper
• Red blood cell fatty acid levels improve GRACE score prediction of 2-yr mortality in patients with myocardial infarction.

  2013cited by this paper
• Platelet Activating Factor-Induced Ceramide Micro-Domains Drive Endothelial NOS Activation and Contribute to Barrier Dysfunction

  2013cited by this paper
• Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial).

  2013cited by this paper
• Extreme lipoprotein(a) levels and improved cardiovascular risk prediction.

  2013cited by this paper
• Hypertension Is Associated with Marked Alterations in Sphingolipid Biology: A Potential Role for Ceramide

  2011cited by this paper
• Gastric Bypass Surgery Reduces Plasma Ceramide Subspecies and Improves Insulin Sensitivity in Severely Obese Patients

  2011cited by this paper
• The Modification of Serum Lipids after Acute Coronary Syndrome and Importance in Clinical Practice

  2011cited by this paper
• Relation between blood and atrial fatty acids in patients undergoing cardiac bypass surgery.

  2010cited by this paper
• Comparison of the efficacy of rosuvastatin versus atorvastatin in reducing apolipoprotein B/apolipoprotein A-1 ratio in patients with acute coronary syndrome: results of the CENTAURUS study.

  2010cited by this paper
• Focus Issue: Biomarkers in Cardiovascular DiseaseClinical Research: Biomarkers in Vascular Disease and HypertensionApolipoprotein(a) Isoforms and the Risk of Vascular Disease: Systematic Review of 40 Studies Involving 58,000 Participants

  2010cited by this paper
• Biological variability of blood omega-3 biomarkers.

  2010cited by this paper
• Prognostic Utility of ApoB/AI, Total Cholesterol/HDL, Non-HDL Cholesterol, or hs-CRP as Predictors of Clinical Risk in Patients Receiving Statin Therapy After Acute Coronary Syndromes: Results From PROVE IT–TIMI 22

  2009cited by this paper
• A NEW SERUM TYPE SYSTEM IN MAN--THE LP SYSTEM.

  2009cited by this paper
• Erythrocyte fatty acid profiles can predict acute non-fatal myocardial infarction.

  2009cited by this paper
• (n-3) Fatty acid content of red blood cells does not predict risk of future cardiovascular events following an acute coronary syndrome.

  2009cited by this paper
• Evidence of free fatty acid interdigitation in stratum corneum model membranes based on ceramide [AP] by deuterium labelling.

  2009cited by this paper
• Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Choleste

  2009cited by this paper
• Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.

  2008cited by this paper
• EPA and DHA in blood cell membranes from acute coronary syndrome patients and controls.

  2008cited by this paper
• Lipid levels after acute coronary syndromes.

  2008cited by this paper
• Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction.

  2007cited by this paper
• Explaining the decrease in U.S. deaths from coronary disease, 1980-2000.

  2007cited by this paper
• ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients Wi

  2004cited by this paper
• High-Dose Atorvastatin Reduces Total Plasma Levels of Oxidized Phospholipids and Immune Complexes Present on Apolipoprotein B-100 in Patients With Acute Coronary Syndromes in the MIRACL Trial

  2004cited by this paper
• Electrophoretic measurement of lipoprotein(a) cholesterol in plasma with and without ultracentrifugation: comparison with an immunoturbidimetric lipoprotein(a) method.

  2004cited by this paper
• Omega-3 Fatty Acids in Cardiac Biopsies From Heart Transplantation Patients: Correlation With Erythrocytes and Response to Supplementation

  2004cited by this paper
• Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease.

  2002cited by this paper
• Usefulness of lipoprotein changes during acute coronary syndromes for predicting postdischarge lipoprotein levels.

  2002cited by this paper
• Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.

  2001cited by this paper
• Measurement of plasma lipids in patients admitted with acute myocardial infarction or unstable angina pectoris.

  2001cited by this paper
• Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study.

  2001cited by this paper
• Upregulation of cholesterol synthesis after acute myocardial infarction--is cholesterol a positive acute phase reactant?

  1999cited by this paper
• Human Vascular Endothelial Cells Are a Rich and Regulatable Source of Secretory Sphingomyelinase

  1998cited by this paper
• Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins.

  1996cited by this paper
• The apolipoprotein (a) gene: a transcribed hypervariable locus controlling plasma lipoprotein (a) concentration

  1992cited by this paper
• Long-term effects of dietary marine omega-3 fatty acids upon plasma and cellular lipids, platelet function, and eicosanoid formation in humans.

  1985cited by this paper
• How soon after myocardial infarction should plasma lipid values be assessed?

  1984cited by this paper
• Plasma-lipid changes after myocardial infarction.

  1971cited by this paper
• Influence of myocardial infarction on plasma-lipoprotein concentration.

  1959cited by this paper
• The power of words.

  1951cited by this paper

• Ceramide in Coronary Artery Disease: Troublesome or Helpful Future Tools in the Assessment of Risk Prediction and Therapy Effectiveness?

  2025cites this paper
• The application of modified mRNA in the treatment and prospective vaccine development for cardiovascular diseases

  2025cites this paper
• Potential Application of Modified mRNA in Cardiac Regeneration

  2024cites this paper
• Insulin Resistance, Obesity, and Lipotoxicity.

  2024cites this paper
• Metabolic signatures in post-myocardial infarction heart failure, including insights into prediction, intervention, and prognosis.

  2023cites this paper
• Potential drug targets for myocardial infarction identified through Mendelian randomization analysis and Genetic colocalization

  2023cites this paper
• The prospect of genomic, transcriptomic, epigenetic and metabolomic biomarkers for the personalized prevention of type 2 diabetes and cardiovascular diseases.

  2023cites this paper
• Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

  2022cites this paper
• Emerging Biomarkers in Acute Coronary Syndromes - A Pathophysiologic Perspective.

  2022cites this paper
• Effects of Dicyclohexyl Phthalate Exposure on PXR Activation and Lipid Homeostasis in Mice

  2021cites this paper
• Lipid metabolism in sickness and in health: Emerging regulators of lipotoxicity.

  2021cites this paper
• Altering Sphingolipid Metabolism Attenuates Cell Death and Inflammatory Response After Myocardial Infarction

  2020cites this paper
• From hemorrhagic stroke to lipid paradox: a double-hit hypothesis underlying low low-density lipoprotein cholesterol related cardiovascular risk—a narrative review

  2020cites this paper
• Sphingolipid composition of circulating extracellular vesicles after myocardial ischemia

  2020cites this paper
• Circulating Ceramide: A New Cardiometabolic Biomarker in Patients With Comorbid Acute Coronary Syndrome and Type 2 Diabetes Mellitus

  2020cites this paper
• Age- and sex-specific reference values for non-HDL cholesterol and remnant cholesterol derived from the Nordic Reference Interval Project (NORIP)

  2019cites this paper
• The immune functions of PCSK9: Local and systemic perspectives

  2019cites this paper
• Association of Diet Quality and Body Mass Index with Serum Ceramides in Middle-aged Adults

  2018cites this paper
• Omega-3 Fatty Acids Improve Size of Lipoproteins and Decrease Electronegative Low-Density Lipoprotein [Ldl(-)] of Brazilian Adults

  2017cites this paper